Role of ventral hippocampal GABAA and NMDA receptors in the anxiolytic effect of carbamazepine in rats using the elevated pous maze test

Pharmacology

Volumn 84, Issue 6, 2009, Pages 356-366

  Rezvanfard, Mehrnaz ^a   Zarrindast, Mohammad Reza ^a,b   Bina, Payvand ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anxiety disorders; Carbamazepine; Elevated plus maze test

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; BICUCULLINE; CARBAMAZEPINE; DAP 5; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; GABAERGIC SYSTEM; HIPPOCAMPUS; MALE; MAZE TEST; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; GABA AGONISTS; GABA ANTAGONISTS; HIPPOCAMPUS; MALE; MAZE LEARNING; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 70449513662     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000256666     Document Type: Article

References (66)

1. van Steveninck A, Wallnofer A, Schoemaker R, Pieters M, Danhof M, van Gerven J, Cohen A: A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44: 267-275.
2. Cowley D, Roy-Byrne P, Radant A, Ritchie J, Greenblatt D, Nemeroff C, Hommer D: Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. Neuropsychopharmacology 1995; 12: 147-157.
3. MacKinnon G, Parker W: Benzodiazepine withdrawal syndrome: a literature review and evaluation. Am J Drug Alcohol Abuse 1982; 9: 19.
4. Rapport D, Calabrese J: Tolerance to fluoxetine. J Clin Psychopharmacol 1993; 13: 361.
5. Rogawski M, Löscher W: The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004; 10: 685-692.
6. Rogawski M, Löscher W: The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004; 5: 553-564.
7. Spina E, Perugi G: Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6: 57-76.
8. Landmark C: Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27.
9. Zaremba P, Bialek M, Blaszczyk B, Cioczek P, Czuczwar S: Non-epilepsy uses of antiepileptic drugs. Pharmacol Rep 2006; 58: 1-12.
10. Golden A, Haut S, Moshé S: Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 2006; 34: 421-432.
11. Ettinger A, Argoff C: Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain. Neurotherapeutics 2007; 4: 75-83.
12. Goodnick P: Anticonvulsants in the treatment of bipolar mania. Expert Opin Pharmacother 2006; 7: 401-410.
13. Mula M, Pini S, Cassano G: The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263-272.
14. Silberstein S: Shared mechanisms and comorbidities in neurologic and psychiatric disorders. Headache 2001; 41: 11-17.
15. Prueter C, Norra C: Mood disorders and their treatment in patients with epilepsy. Am Neuropsychol Assoc 2005; 17: 20-28.
16. Ettinger A, Reed M, Goldberg J, Hirschfeld R: Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005; 65: 535-540.
17. Van Ameringen M, Mancini C, Pipe B, Bennett M: Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 2004; 64: 2199-2200.
18. Lydiard R: The role of GABA in anxiety disorders. J Clin Psychiatry Suppl 2003; 64: 21-27.
19. Nemeroff C: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 2003; 37: 133-146.
20. Quirk G, Gehlert D: Inhibition of the amygdala: key to pathological states? Ann NY Acad Sci 2003; 985: 263-272.
21. Davidson R: Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 2002; 51: 68-80.
22. Bannerman D, Rawlins J, McHugh S, Deacon R, Yee B, Bast T, Zhang W, Pothuizen H, Feldon J: Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 2004; 28: 273-283.
23. Davis M, Shi C: The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann NY Acad Sci 1999; 877: 281-291.
24. Bergink V, van Megen H, Westenberg H: Glutamate and anxiety. Eur Neuropsychopharmacol 2004; 14: 175-183.
25. McHugh S, Deacon R, Rawlins J, Bannerman D: Amygdala and ventral hippocampus contribute differentially to mechanisms of fear and anxiety. Behav Neurosci 2004; 118: 63-78.
26. Bast T, Feldon J: Hippocampal modulation of sensorimotor processes. Progr Neurobiol 2003; 70: 319-345.
27. Engin E, Treit D: The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 2007; 18: 365-374.
28. Pentkowski N, Blanchard D, Lever C, Litvin Y, Blanchard R: Effects of lesions to the dorsal and ventral hippocampus on defensive behaviors in rats. Eur J Neurosci 2006; 23: 2185-2196.
29. Sajdyk T, Shekhar A: Excitatory amino acid receptors in the basolateral amygdala regulate anxiety responses in the social interaction test. Brain Res 1997; 764: 262-264.
30. Carobrez A, Teixeira K, Graeff F: Modulation of defensive behavior by periaqueductal gray NMDA/glycine-B receptor. Neurosci Biobehav Rev 2001; 25: 697-709.
31. Macdonald R, Kelly K: Antiepileptic drug mechanisms of action. Epilepsia 1995; 36: 2-12.
32. Ford N: The use of anticonvulsants in posttraumatic stress disorder: case study and overview. J Traum Stress 1996; 9: 857-863.
33. Lawlor B: Carbamazepine, alprazolam withdrawal, and panic disorder. Am J Psychiatry 1987; 144: 265-266.
34. Tondo L, Burrai C, Scamonatti L, Toccafondi F, Poddighe A, Minnai G, Tundo A, Floris G: Carbamazepine in panic disorder. Am J Psychiatry 1989; 146: 558-559.
35. Zangrossi Junior H, Leite J, Graeff F: Anxiolytic effect of carbamazepine measured in the elevated plus maze. Braz J Med Biol Res 1989; 22: 703-705.
36. Martijena I, Lacerra C, Molina V: Carbamazepine normalizes the altered behavioral and neurochemical response to stress in benzodiazepine-withdrawn rats. Eur J Pharmacol 1997; 330: 101-108.
37. Nowakowska E, Kus K, Czubak A, Glowacka D, Matschay A: Some behavioural effects of carbamazepine-Comparison with haloperidol. J Physiol Pharmacol 2007; 58: 253-264.
38. Almeida R, Leite J: Effects of acute or chronic carbamazepine on experimentally-induced conflict in the rat. Psychopharmacology 1990; 100: 227-229.
39. Perucca E: Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001; 15: 405-417.
40. Perucca E: An introduction to antiepileptic drugs. Epilepsia 2005; 46: 31-37.
41. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 6. Sydney, Academic Press, 2007.
42. Morris R, Moser E, Riedel G, Martin S, Sandin J, Day M, O'Carroll C: Elements of a neurobiological theory of the hippocampus: the role of activity-dependent synaptic plasticity in memory. Philos Trans R Soc Lond B Biol Sci 2003; 358: 773-786.
43. Pinheiro S, Zangrossi H Jr, Del-Ben C, Graeff F: Elevated mazes as animal models of anxiety: effects of serotonergic agents. An Acad Bras Cien 2007; 79: 71-85.
44. Carobrez A, Bertoglio L: Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 2005; 29: 1193-1205.
45. Pellow S, Chopin P, File S, Briley M: Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14: 149-167.
46. Kuo C: A common anticonvulsant binding site for phenytoin, carbamazepine, and lamotrigine in neuronal Na+ channels. Mol Pharmacol 1998; 54: 712-721.
47. Saad S, Khayyal M, Attia A, Saad E: Influence of certain calcium-channel blockers on some aspects of lorazepam-dependence in mice. J Pharm Pharmacol 1997; 49: 322-328.
48. Foster A, Kemp J: Glutamate-and GABAbased CNS therapeutics. Curr Opin Pharmacol 2006; 6: 7-17.
49. Granger P, Biton B, Faure C, Vige X, Depoortere H, Graham D, Langer S, Scatton B, Avenet P: Modulation of the gamma-aminobutyric acid type a receptor by the antiepileptic drugs carbamazepine and phenytoin. Mol Pharmacol 1995; 47: 1189-1196.
50. Sanders S, Shekhar A: Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995; 52: 701-706.
51. Rezayat M, Roohbakhsh A, Zarrindast M, Massoudi R, Djahanguiri B: Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety. Physiol Behav 2005; 84: 775-782.
52. Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent J, Belzung C, Fritschy J, Lüscher B, Mohler H: Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci 1999; 2: 833-839.
53. Low K, Crestani F, Keist R, Benke D, Brunig I, Benson J, Fritschy J, Rulicke T, Bluethmann H, Mohler H: Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000; 290: 131-134.
54. Lancaster J, Davies J: Carbamazepine inhibits NMDA-induced depolarizations in cortical wedges prepared from DBA/2 mice. Experientia 1992; 48: 751-753.
55. Lampe H, Bigalke H: Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1990; 1: 26.
56. Poleszak E: Benzodiazepine/GABA(A) receptors are involved in magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep 2008; 60: 483-489.
57. Wiley J, Cristello A, Balster R: Effects of siteselective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice. Eur J Pharmacol 1995; 294: 101-107.
58. Kotlinska J, Liljequist S: A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701,324. Psychopharmacology 1998; 135: 175-181.
59. Karcz-Kubicha M, Jessa M, Nazar M, Plaznik A, Hartmann S, Parsons C, Danysz W: Anxiolytic activity of glycine-b antagonists and partial agonists-No relation to intrinsic activity in the patch clamp. Neuropharmacology 1997; 36: 1355-1367.
60. Plaznik A, Palejko W, Nazar M, Jessa M: Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 1994; 4: 503-512.
61. Fagg G, Olpe H, Schmutz M, Pozza M, van Riezen H, Bittiger H, Angst C, Brundish D, Allgeier H, Heckendorn R: CGP 37849 and CGP 39551: novel competitive N-methyl-D-aspartate receptor antagonists with potent oral anticonvulsant activity. Prog Clin Biol Res 1990; 361: 421-427.
62. Guimarães F, Carobrez A, Aguiar J, Graeff F: Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey. Psychopharmacology 1991; 103: 91-94.
63. Kim M, McGaugh J: Effects of intra-amygdala injections of NMDA receptor antagonists on acquisition and retention of inhibitory avoidance. Brain Res 1992; 585: 35-48.
64. Nascimento Häckl LP, Carobrez AP: Distinct ventral and dorsal hippocampus AP5 anxiolytic effects revealed in the elevated plus-maze task in rats. Neurobiol Learn Mem 2007; 88: 177-185.
65. Fedosiewicz-Wasiluk M, Holy Z, Wisniewska R, Wisniewski K: The influence of NMDA, a potent agonist of glutamate receptor, on behavioral activity of rats with experimental hyperammonemia evoked by liver failure. Amino Acids 2005; 28: 111-117.
66. Moraes C, Bertoglio L, Carobrez A: Interplay between glutamate and serotonin within the dorsal periaqueductal gray modulates anxiety-related behavior of rats exposed to the elevated plus-maze. Behav Brain Res 2008; 194: 181-186.